Stock Quote
Vertex Pharmaceuticals Incorporated (VRTX.O) (Nasdaq)
$39.36
4:00pm EST
+2.13%
$38.54
$38.96
1,437,130
$39.73
$38.66
$41.75
$20.94
0.63
2,468,540
VRTX.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Emmens, Matthew | Chairman of the Board, President, Chief Executive Officer | -- |
| Smith, Ian | Chief Financial Officer, Executive Vice President | 2,703,820 |
| Mueller, Peter | Executive Vice President - Global Research and Development, Chief Scientific Officer | 3,113,860 |
Profile
Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company’s principal drug candidate, is an oral hepatitis C protease inhibitor and an antiviral treatment... Full Description
Company Address
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge MA 02139
P: +1617.4446100
F: +1617.4446680
130 Waverly Street
Cambridge MA 02139
P: +1617.4446100
F: +1617.4446680
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Schering-Plough Corporation | -- | -- |
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| Wyeth | -- | -- |
| VRTX.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 69.27 | 29.90 |
| ROI(TTM) | -56.15 | 2.35 |
| ROE(TTM) | -130.57 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -0.82 |
| EPS Est. (Current Year) | -3.63 |
| Total Revenue | $24.96M |
| Net Income | $-149.57M |
| EPS | $-0.84 |
